Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer

被引:90
作者
Clarke, SJ
Abratt, R
Goedhals, L
Boyer, MJ
Millward, MJ
Ackland, SP
机构
[1] Sydney Canc Ctr, Camperdown, NSW 2050, Australia
[2] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa
[3] Natl Hosp, Bloemfontein, South Africa
[4] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[5] Mater Hosp, Newcastle, NSW, Australia
关键词
non-small-cell lung cancer; pemetrexed; phase II;
D O I
10.1093/annonc/mdf115
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-naive patients with surgically incurable non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients received pemetrexed 600 mg/m(2) every 3 weeks. Restaging was performed after every two cycles of therapy and toxicity was assessed at each cycle of pemetrexed. In the absence of disease progression or undue toxicity, treatment was continued for a maximum of 12 cycles. Results: Fifty-nine patients (median age 59 years; range 39-74 years) received a median Of four cycles of pemetrexed. Nineteen patients (32%) had a ECOG performance status (PS) of two and 39 patients (66%) had stage IV disease. The most common histological sub-types were adenocarcinoma (20 patients, 34%) and large cell (18 patients, 31%). Sixteen patients (27%) had received prior radiotherapy. Nine patients achieved a partial response for an overall response rate of 15.8% (95% confidence interval Cl 7% to 28%). The median duration of response was 4.9 months, and the median survival was 7.2 months. The principal toxicities were myelosuppression and rash. While grade 3 or 4 neutropenia was seen in 25 patients (42%), only two patients (3%) developed grade 3 infection. Eighteen patients (31%) developed grade 3 or 4 cutaneous toxicity, which improved with prophylactic oral dexamethasone administered for 3 days beginning the day before pemetrexed treatment. Asymptomatic elevations in hepatic biochemistry (especially alanine transaminase and aspartate transaminase) were seen in 47 patients (80%); however, these did not interfere with the dose or schedule of pemetrexed and returned to normal levels throughout the study. Conclusions: This is the largest study confirming the encouraging single-agent activity of pemetrexed in chemotherapy-naive patients with NSCLC. In addition, this study demonstrates that a dose of 600 mg/m(2) can be delivered safely; however, treatment should be restricted to patients with a PS of 0 or 1. The results of combination studies are awaited with interest.
引用
收藏
页码:737 / 741
页数:5
相关论文
共 50 条
[41]   Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer [J].
Spigel, David R. ;
Hainsworth, John D. ;
Barton, John H. ;
Patton, Jeffrey F. ;
Zubkus, John D. ;
Simons, Lisa ;
Griner, Paula ;
Burris, Howard A., III ;
Greco, F. Anthony .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) :841-845
[42]   Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial [J].
Nicolson, Marianne C. ;
Fennell, Dean A. ;
Ferry, David ;
O'Byrne, Kenneth ;
Shah, Riyaz ;
Potter, Vanessa ;
Skailes, Geraldine ;
Upadhyay, Sunil ;
Taylor, Paul ;
Andre, Valerie ;
Nguyen, Tuan S. ;
Myrand, Scott P. ;
Visseren-Grul, Carla ;
Das, Mayukh ;
Kerr, Keith M. .
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) :930-939
[43]   Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer - Phase II study [J].
Mohedano, NM ;
Rovira, PS ;
Barriuso, AL ;
Morales, MF ;
Magan, BM ;
Morago, AJ ;
Quintela, IP ;
Garcia, RD ;
Flores, EF ;
Moreno, MAM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04) :363-365
[44]   Preliminary result of phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small-cell lung cancer in Chinese patients [J].
Hsu, JW ;
Hsu, JY ;
Chiang, CD .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (05) :487-490
[45]   A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study [J].
Masahiro Tabata ;
Toshiyuki Kozuki ;
Hiroshi Ueoka ;
Katsuyuki Kiura ;
Shingo Harita ;
Atsuhiko Tada ;
Takuo Shibayama ;
Nagio Takigawa ;
Toshiro Yonei ;
Kenichi Gemba ;
Yoshihiko Segawa ;
Daizo Kishino ;
Shinya Tada ;
Shunkichi Hiraki ;
Mitsune Tanimoto .
Cancer Chemotherapy and Pharmacology, 2007, 60 :53-59
[46]   A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study [J].
Tabata, Masahiro ;
Kozuki, Toshiyuki ;
Ueoka, Hiroshi ;
Kiura, Katsuyuki ;
Harita, Shingo ;
Tada, Atsuhiko ;
Shibayama, Takuo ;
Takigawa, Nagio ;
Yonei, Toshiro ;
Gemba, Kenichi ;
Segawa, Yoshihiko ;
Kishino, Daizo ;
Tada, Shinya ;
Hiraki, Shunkichi ;
Tanimoto, Mitsune .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) :53-59
[47]   Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer [J].
Otsubo, Kohei ;
Nosaki, Kaname ;
Imamura, Chiyo K. ;
Ogata, Hiroaki ;
Fujita, Akitaka ;
Sakata, Shinya ;
Hirai, Fumihiko ;
Toyokawa, Gouji ;
Iwama, Eiji ;
Harada, Taishi ;
Seto, Takashi ;
Takenoyama, Mitsuhiro ;
Ozeki, Takeshi ;
Mushiroda, Taisei ;
Inada, Mieko ;
Kishimoto, Junji ;
Tsuchihashi, Kenji ;
Suina, Kentaro ;
Nagano, Osamu ;
Saya, Hideyuki ;
Nakanishi, Yoichi ;
Okamoto, Isamu .
CANCER SCIENCE, 2017, 108 (09) :1843-1849
[48]   Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial [J].
G P Stathopoulos ;
J Dimitroulis ;
D Antoniou ;
C Katis ;
D Tsavdaridis ;
O Armenaki ;
C Marosis ;
P Michalopoulou ;
T Grigoratou ;
J Stathopoulos .
British Journal of Cancer, 2005, 93 :1106-1111
[49]   A phase II study of the docetaxel-carboplatin chemotherapy regimen in advanced non-small-cell lung cancer [J].
Tsavaris, N ;
Kosmas, C ;
Skopelitis, E ;
Gennatas, K ;
Zorbala, A ;
Papas, P ;
Gouveris, P ;
Antypas, G ;
Rokana, S ;
Tzelepis, G .
LUNG, 2005, 183 (06) :405-416
[50]   Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer [J].
Kikuchi, J ;
Yamazaki, K ;
Kinoshita, I ;
Asahina, H ;
Imura, M ;
Kikuchi, E ;
Konishi, J ;
Shinagawa, N ;
Oki, H ;
Dosaka-Akita, H ;
Nishimura, M .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (09) :505-509